A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1
315
about 5.5 years
18+
25 sites in AL, CA, IA +5
What this study is about
Researchers are testing the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in people with solid tumors. The trial will also trial the side effects of this drug.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take PF-08046054
- 2.Take pembrolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Number of participants with adverse events (AEs), Number of participants with dose-limiting toxicities (DLTs), Number of participants with laboratory abnormalities
Secondary: Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by investigator assessment, Duration of objective response (DOR) per RECIST v1.1 by investigator assessment, Incidence of anti-drug antibodies (ADAs), Overall survival (OS), PK parameter - Maximum concentration (Cmax), PK parameter - Trough concentration (Ctrough), Pharmacokinetic (PK) parameter - Area under the concentration-time curve (AUC), Progression-free survival (PFS) per RECIST v1.1 by investigator assessment
Oncology